Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Autolus to support UK network of Advanced Therapies Treatment Centres

Autolus
Posted on: 16 Mar 18

London, 15 March 2018 – Autolus Limited, a UK-based biopharmaceutical company developing next-generation programmed T cell therapies for the treatment of cancer, is pleased to be part of the Northern Alliance Advanced Therapies Treatment Centre (NAATTC) consortium and to support the Innovate Manchester Advanced Therapy Centre Hub (iMATCH) consortium, each of which have been awarded a £7 million grant from Innovate UK, the government’s innovation agency, pursuant to the £146 million Industrial Strategy Medicines Manufacturing Challenge. This funding from Innovate UK is intended to help facilitate the development, potential commercialisation and implementation of cell, gene and tissue engineered therapies in the United Kingdom.

 

The grants, announced earlier this week by The Rt Hon Greg Clark, Secretary of State for Business, Energy and Industrial Strategy, will support the funding of a network of advanced therapies treatment centres (ATTC) in the United Kingdom, coordinated by the Cell and Gene Therapy Catapult, that will work with collaborators such as Autolus to address issues relating to the development, manufacture and supply, evaluation, funding and adoption of this new generation of potential therapies with the aim of increasing the capacity of the National Health Service (NHS) to deliver advanced therapies to patients.

 

Dr Christian Itin, CEO of Autolus Limited, commented:

“We are delighted to collaborate with our partners in the NAATTC and to support the iMATCH consortium, and look forward to continuing to work together and share expertise to aid NAATTC’s goal of facilitating the development of advanced therapies, such as our programmed T cell product candidates, which have potential as treatment options for patients with few or no alternatives. We are grateful for the support and foresight of the UK government and Innovate UK in recognising the potential of this type of therapy by investing early in the necessary infrastructure to facilitate development of these products and adoption within the NHS, and providing the right environment for UK companies, such as Autolus, to remain at the forefront of innovation in this exciting field.”

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 16/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.